Selected Approaches to Disrupting Protein-Protein Interactions within the MAPK/RAS Pathway

被引：9

作者：

Harwood, Stephen J. ^{[1
]}

Smith, Christopher R. ^{[1
]}

Lawson, J. David ^{[1
]}

Ketcham, John M. ^{[1
]}

机构：

[1] Mirati Therapeut, 3545 Cray Court, San Diego, CA 92121 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 08期

关键词：

MAPK; KRAS; RAS; protein-protein interactions; X-ray crystallography; RAF INHIBITOR; DRUG DISCOVERY; COVALENT INHIBITOR; STRUCTURAL BASIS; SMALL MOLECULES; HUMAN CANCER; SH3; DOMAIN; BRAF; MELANOMA; SURVIVAL;

D O I：

10.3390/ijms24087373

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Within the MAPK/RAS pathway, there exists a plethora of protein-protein interactions (PPIs). For many years, scientists have focused efforts on drugging KRAS and its effectors in hopes to provide much needed therapies for patients with KRAS-mutant driven cancers. In this review, we focus on recent strategies to inhibit RAS-signaling via disrupting PPIs associated with SOS1, RAF, PDE delta, Grb2, and RAS.

引用

页数：21

共 123 条

[1]

[Anonymous], SCI PRES

[2] The road less traveled: modulating signal transduction enzymes by inhibiting their protein-protein interactions [J].

Arkin, Michelle R. ;

Whitty, Adrian .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2009, 13 (03) :284-290

[3] Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream [J].

Arkin, MR ;

Wells, JA .

NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (04) :301-317

[4] Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors [J].

Arora, Rohit ;

Di Michele, Michela ;

Stes, Elisabeth ;

Vandermarliere, Elien ;

Martens, Lennart ;

Gevaert, Kris ;

Van Heerde, Erika ;

Linders, Joannes T. M. ;

Brehmer, Dirk ;

Jacoby, Edgar ;

Bonnet, Pascal .

JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (04) :1818-1831

[5] A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling [J].

Athuluri-Divakar, Sai Krishna ;

Vasquez-Del Carpio, Rodrigo ;

Dutta, Kaushik ;

Baker, Stacey J. ;

Cosenza, Stephen C. ;

Basu, Indranil ;

Gupta, Yogesh K. ;

Reddy, M. V. Ramana ;

Ueno, Lynn ;

Hart, Jonathan R. ;

Vogt, Peter K. ;

Mulholland, David ;

Guha, Chandan ;

Aggarwal, Aneel K. ;

Reddy, E. Premkumar .

CELL, 2016, 165 (03) :643-655

[6] SOS GEFs in health and disease [J].

Baltanas, Fernando C. ;

Zarich, Natasha ;

Rojas-Cabaneros, Jose M. ;

Santos, Eugenio .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1874 (02)

[7] KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation [J].

Bekaii-Saab, Tanios S. ;

Spira, Alexander I. ;

Yaeger, Rona ;

Buchschacher, Gary L. ;

McRee, Autumn Jackson ;

Sabari, Joshua K. ;

Johnson, Melissa Lynne ;

Barve, Minal A. ;

Hafez, Navid ;

Velastegui, Karen ;

Christensen, James G. ;

Kheoh, Thian ;

Der-Torossian, Hirak ;

Rybkin, Igor I. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

[8] PROTAC targeted protein degraders: the past is prologue [J].

Bekes, Miklos ;

Langley, David R. ;

Crews, Craig M. .

NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (03) :181-200

[9] Modulation of protein-protein interactions with small organic molecules [J].

Berg, T .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2003, 42 (22) :2462-2481

[10] A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS [J].

Bery, Nicolas ;

Miller, Ami ;

Rabbitts, Terry .

NATURE COMMUNICATIONS, 2020, 11 (01)

← 1 2 3 4 5 6 7 8 9 10 →